Kuzkina et al. Efficacy of IL-6i with olokizumab on depression in RA. There appear to be some benefit but anti-depressants still needed. Group 1 is olokizumab alone, other 2 groups have anti-depressants also. @RheumNow #ACR25 Abstr#1323 https://t.co/h2ExYQgKTL

• https://x.com/RichardPAConway/status/1982840462747587012/photo/1

Mayer et al. NSAIDs in IBD. Retrospective cohort study. 250000 individuals. Non-inferiority study. No increased IBD-related hospitalisation in UC, but an increase in all-cause hospitalisation. @RheumNow #ACR25 Abstr#1434 https://t.co/he2Xmcqslk

• https://x.com/RichardPAConway/status/1982839959313662215/photo/1

Post Hoc analysis from SELECT-GCA Increased rate of herpes zoster for 26wk steroid-UPA 15mg (7.3% vs 4.2% 52wk steroid-plbo) but lower rate of SERIOUS infections (7.9% vs 12.7% 52wk steroid-plbo) Zoster risk is real; steroids are the bigger problem @Rheumnow #ACR25 Abstr#0895 https://t.co/IKzO2J4hLH

• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1
• https://x.com/EBRheum/status/1982839959070687309/photo/1

@RheumNow on virtual learning: It’s integrated in clinical care, research and #MedEd How to manage info overload? - schedule, make use of tools - use AI to curate, analyze & focus #ACR25 @rheumarhyme https://t.co/ogCezlnxUP

• https://x.com/RHEUMarampa/status/1982839789155127776/photo/1
• https://x.com/RHEUMarampa/status/1982839789155127776/photo/1
• https://x.com/RHEUMarampa/status/1982839789155127776/photo/1

X-sectional study by Dr Toledano et al showed that 20% (46/230) PsA pts had restless leg syndrome (RDS). Pts w/ RDS: - Polyarthritis ⬆️ Swollen jts ⬆️ Fatigue, anxiety, depression ⬆️ Dse activity Poor sleep quality Polyarthritis & Pso: assocd w/ RDS #ACR25 @RheumNow Abs1413 https://t.co/8Ds3TgLjs1

• https://x.com/RHEUMarampa/status/1982839712034230299/photo/1

In ICONIC-LEAD, adolescents (12 to <18 years) with moderate-to-severe psoriasis treated with icotrokinra (ICO) achieved Investigator Global Assessment (IGA) 0/1 in 84.1% vs 27.3% (placebo) and PASI 90 in 70.5% vs 13.6% at Week 16. Week 24 responses reached 88.6%. Safety profile https://t.co/L7h8BlnWaO

• https://x.com/synovialjoints/status/1982839707932483871/photo/1

Concerns using dupilumab in EGPA due to secondary eosinophilia What about when combined with IL-5 therapy? 16 pt on dupi + IL5 agent - if dupi alone caused eosinophilia -> quelled by IL-5 - no eosinophilia when dupi added to IL-5 - effective but slow @RheumNow #ACR25 Abst 1605

Case series of 5 patients with binutuzumab (CD20) in AAV Short story short; it worked. Of course it worked. Obviously it worked. Everyone knew it would work. Why aren't we doing more TRIALS with new/better B cell inhibitors in AAV? #ACR25 @RheumNow Abstr#1601 https://t.co/H6Zz3Tf3xo

• https://x.com/EBRheum/status/1982839203819090389/photo/1

Don’t forget 👇 #lcSSc Pts can get and progress #ILD 1/3 of #limited #cutaneous #systemic #sclerosis #scleroderma GET ILD From #EUSTAR >14% progress Esp +Scl70 Remember to screen #CREST Pts & allow these Pts into lung disease trials #ACR25 @RheumNow @ACRheum abst#0879 https://t.co/X15tUgClzN

• https://x.com/Janetbirdope/status/1982838827770073577/photo/1
• https://x.com/Janetbirdope/status/1982838827770073577/photo/1
• https://x.com/Janetbirdope/status/1982838827770073577/photo/1

Rural RA care looks different but not less intensive: DMARD and GC use matched urban rates, yet rural pts often managed by PCPs had twice the opioid use. ACR's Rheum for Primary Care resource can help address access gap and improve RA care @RheumNow #ACR25 Abstract#1025

Liraglutide had decreased synovial inflammation and fibrosis in mouse models, however dexamethasone didnt have changes in fibrosis scores Abst#1734 #ACR25 @RheumNow https://t.co/O4JYGtDD5N

• https://x.com/bella_mehta/status/1982837788166017285/photo/1

Analysis from FVSG identified 36pts with anti-rituximab antibodies In AAV, lookout for this in pts who are MPO+ & w/higher CD19 at 6 mos. Worse relapse free survival in both AAV & CRYO! @TerrierBen can you share the prevalence of these abs? #ACR25 @RheumNow #ACRBest abstr#1604 https://t.co/Nyx6JxbvUk

• https://x.com/EBRheum/status/1982837442140148004/photo/1
• https://x.com/EBRheum/status/1982837442140148004/photo/1

A combined biomarker assay may predict which AAV patients will not respond to RTX therapy A next step towards precision / personalized rheumatology? @RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9

• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1
• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1

Safety & benefit of #Deucravacitinib in #SLE #LTE #PAISLEY #RCT 👇 over 4 yrs Stable response sustained over 4 yrs No new Safety signals Await Ph3 RCT results - fully enrolled #SoTyktu Abst#LB10 #ACR25 @RheumNow @ACRheum https://t.co/ZpmzOYVnq9

• https://x.com/Janetbirdope/status/1982835982748745866/photo/1

#1263 More from our health literacy work! @KingsCollegeNHS, 11 distinct health literacy profiles were identified from 263 rheum patients. Lower literacy linked to unemployment & non-White ethnicity, highlighting equity gaps in care & need for improved resources @RheumNow #ACR25 https://t.co/QxzMFLykyE

• https://x.com/DrMiniDey/status/1982835932655964566/photo/1